Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Arterial Hypertension
Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult…
- Trial name
- NCT04903730
- Testing
- AER-901 Solution for Nebulization
- Where
- Australia
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Aerami Therapeutics
Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH)
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation.
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt
- Trial name
- Gen-PoPH-CPSS (NCT07314814)
- Testing
- targeted gene panels analysis, whole genome analysis
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prof. Valérie Mc Lin
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
- Trial name
- NCT05934526
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 166 sites in United States, Argentina and 29 more
- Volunteers
- 390 people
- Sponsor
- GB002, Inc.
Pulmonary Arterial Hypertension
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study. Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish…
- Trial name
- ORCHESTRA (NCT02081690)
- Testing
- Macitentan
- Where
- 39 sites in France, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
Previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). However, all of these studies are sequential combination therapy, for example, by adding sildenafil to…
- Trial name
- BIPH (NCT01712997)
- Testing
- Iloprost, Bosentan
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Air Force Military Medical University, China
Pulmonary Arterial Hypertension
[18F]FES PET/CT in PAH
In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer…
- Trial name
- NCT02899533
- Testing
- [18F] FES
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pulmonary Hypertension, Pulmonary Hypertension Associated With HFpEF
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study
this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment…
- Trial name
- NCT07662655
- Testing
- Percutaneous Pulmonary Artery Denervation (PADN), Control group (receiving standard medical therapy alone)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiamen Cardiovascular Hospital, Xiamen University
Pulmonary Hypertension
Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure
A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.
- Trial name
- PADN-5 (NCT02220335)
- Testing
- Pulmonary arterial denervation, Standard treatment
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension, Heart Defects, Congenital
The Effects of the Otago Exercise Program
The objective of this experimental study is to conduct a comparative evaluation of the effects of a supervised Otago Exercise Program (OEP) functional exercise capacity, blood lactate levels, dyspnea, fatigue, peripheral muscle…
- Trial name
- NCT06172790
- Testing
- Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Idiopathic Pulmonary Arterial Hypertension
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
- Trial name
- NCT07558460
- Testing
- Virtual Reality Group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pressures in the blood vessels of the lungs that is not caused by another disease processes.
- Trial name
- TYEGER (NCT04280523)
- Testing
- ESR-specific PET scan
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP…
- Trial name
- NCT05649748
- Testing
- Treprostinil Palmitil
- Where
- 45 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Hypertension
Losartan Therapy in Pulmonary Hypertension
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and…
- Trial name
- NCT00519870
- Testing
- nifedipine, losartan, losartan
- Sponsor
- Baskent University